Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $1.10B.
ENTERPRISE VALUE (EV)
$1.10B
Taysha Gene Therapies, Inc.
Market Cap
$1.40B
Enterprise Value (EV)
$1.10B
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | $1.40B | $1.10B |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | $1.28B |
| Braveheart Bio, Inc. (BRVE)vs › | $1.40B | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | $1.55B |
| The Pennant Group, Inc. (PNTG)vs › | $1.39B | $1.87B |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.42B | $2.50B |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.37B | $1.24B |
| Certara, Inc. (CERT)vs › | $1.44B | $1.55B |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | $1.31B |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | $1.32B |
Market Cap
$1.40B
Total Debt
$18.17M
Cash
$319.77M
Enterprise Value
$1.10B
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
